Rainbow Child.

INR
1,415.50
-2.4 (-0.17%)
BSENSE

Jun 16, 09:29 AM

BSE+NSE Vol: 3.33 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.33 lacs (80,104.38%) Volume

Shareholding (Mar 2026)

FII

17.24%

Held by 126 FIIs

DII

21.12%

Held by 28 DIIs

Promoter

49.84%

Why is Rainbow Childrens Medicare Ltd falling/rising?

16-Jun-2026

As of 15-Jun, Rainbow Childrens Medicare Ltd's stock price is rising to 1,417.90, driven by strong performance metrics, including a 5.81% return over two days, high management efficiency, and increased investor participation. The stock is trading above key moving averages, reflecting a robust upward trend and positive investor sentiment.

As of 15-Jun, Rainbow Childrens Medicare Ltd's stock price is rising, currently at 1,417.90, reflecting an increase of 54.25 (3.98%). This upward movement can be attributed to several factors. The stock has outperformed its sector by 4.4% today and has experienced consecutive gains over the last two days, with a total return of 5.81% during this period. Additionally, the stock reached an intraday high of Rs 1424.5, marking a 4.46% increase.<BR><BR>The company is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 3.27% against the 5-day average. <BR><BR>Financially, Rainbow Childrens Medicare Ltd demonstrates high management efficiency, evidenced by a return on capital employed (ROCE) of 19.70% and a low debt to EBITDA ratio of 1.64 times, suggesting a strong ability to service its debt. The company reported its highest quarterly net sales at Rs 459.90 crore and a record profit after tax of Rs 78.43 crore, contributing to positive investor sentiment. Additionally, high institutional holdings at 38.37% indicate confidence from more sophisticated investors who can analyze the company's fundamentals effectively. These factors collectively contribute to the stock's rising price.

View full answer

What does Rainbow Child. do?

11-Jun-2026

Rainbow Childrens Medicare Ltd is a small-cap company in the hospital industry, reporting net sales of 460 Cr and a net profit of 77 Cr for the quarter ending March 2026. It has a market cap of INR 13,468 Cr, a P/E ratio of 48.00, and a dividend yield of 0.23%.

Overview:<BR>Rainbow Childrens Medicare Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as Rainbow Children's Medicare Private Limited in 1998 and later converted to a public limited company, changing its name to Rainbow Children's Medicare Limited on November 20, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 460 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 77 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 13,468 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 48.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.23%<BR>- Debt-Equity: 0.27<BR>- Return on Equity: 16.97%<BR>- Price to Book: 8.13<BR><BR>Contact Details:<BR>Registrar Address: Not available.

View full answer

How big is Rainbow Child.?

11-Jun-2026

As of 10th June, Rainbow Childrens Medicare Ltd has a market capitalization of 13,468.00 Cr, with recent net sales of 1,703.08 Cr and a net profit of 278.32 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Rainbow Childrens Medicare Ltd has a market capitalization of 13,468.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,703.08 Cr, while the sum of Net Profit for the same period is 278.32 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,468.19 Cr, and Total Assets amount to 2,347.40 Cr.

View full answer

Who are in the management team of Rainbow Child.?

11-Jun-2026

The management team of Rainbow Child includes Ramesh Kancharla (Chairman & Managing Director), Dinesh Kumar Chirla (Whole-time Director), and five Independent Directors: Aluri Rao Srinivasa, Anil Dhawan, Sundari Raviprasad Pisupati, Santanu Mukherjee, and Ashish Kapil (Company Secretary & Compliance Officer).

The management team of Rainbow Child includes the following individuals:<BR><BR>1. Ramesh Kancharla - Chairman & Managing Director<BR>2. Dinesh Kumar Chirla - Whole-time Director<BR>3. Aluri Rao Srinivasa - Independent Director<BR>4. Anil Dhawan - Independent Director<BR>5. Sundari Raviprasad Pisupati - Independent Director<BR>6. Santanu Mukherjee - Independent Director<BR>7. Ashish Kapil - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or contributions, feel free to ask!

View full answer

Who are the peers of the Rainbow Child.?

11-Jun-2026

Peers of Rainbow Child include Aster DM Health, Narayana Hrudaya, Global Health, and others. Management risk is excellent for several peers, with varying growth rates and capital structure ratings; Yatharth Hospital leads in 1-year returns at 57.94%, while Rainbow Child has a return of -3.06%.

Peers: The peers of Rainbow Child are Aster DM Health., Narayana Hrudaya, Global Health, Krishna Institu., Dr Agarwal's Hea, Health.Global, Jupiter Life Lin, Yatharth Hospit., and Jeena Sikho.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aster DM Health., Narayana Hrudaya, Global Health, Krishna Institu., Jupiter Life Lin, and Rainbow Child., while Average management risk is found at Dr Agarwal's Hea and Health.Global, and the rest. Growth is Excellent at Narayana Hrudaya and Jeena Sikho, while Good growth is noted at Dr Agarwal's Hea, Yatharth Hospit., and the rest. Below Average growth is seen at Aster DM Health., Global Health, Krishna Institu., and Jupiter Life Lin. Capital Structure ratings show Excellent at Global Health and Jupiter Life Lin, Good at Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, and Rainbow Child., while Average is found at Health.Global and the rest.<BR><BR>Return Snapshot: Yatharth Hospit. has the highest 1-year return at 57.94%, while Jeena Sikho has the lowest with an N/A return, and Rainbow Child.'s 1-year return of -3.06% is lower than both. Additionally, Health.Global and Jeena Sikho have negative six-month returns.

View full answer

Should I buy, sell or hold Rainbow Childrens Medicare Ltd?

09-Jun-2026

Are Rainbow Childrens Medicare Ltd latest results good or bad?

29-Jan-2026

Rainbow Childrens Medicare Ltd's latest results show mixed performance, with a year-on-year profit growth of 5.59% but a quarter-on-quarter net profit decline of 3.61% and compressed operating margins, indicating operational challenges and raising concerns about sustainability. Overall, the results are more concerning than encouraging.

The latest results for Rainbow Childrens Medicare Ltd indicate a mixed performance, leaning towards the negative side. While the company achieved a year-on-year profit growth of 5.59%, it faced significant challenges in the most recent quarter. The net profit declined by 3.61% quarter-on-quarter to ₹72.53 crores, and revenue growth was minimal at just 0.15% sequentially. <BR><BR>Moreover, the operating margin has also compressed, falling to 33.0%, which is a decline from the previous quarter. This margin pressure, combined with the tepid revenue growth, raises concerns about the sustainability of the company's expansion in a competitive healthcare landscape. <BR><BR>Overall, while there are some positive year-on-year metrics, the sequential declines in both net profit and operating margin suggest that the company is grappling with operational challenges, making the latest results more concerning than encouraging.

View full answer

When is the next results date for Rainbow Childrens Medicare Ltd?

22-Jan-2026

The next results date for Rainbow Childrens Medicare Ltd is January 28, 2026.

The next results date for Rainbow Childrens Medicare Ltd is scheduled for January 28, 2026.

View full answer

Is Rainbow Child. technically bullish or bearish?

02-Dec-2025

As of December 1, 2025, the technical trend is mildly bearish, influenced by bearish indicators from the weekly MACD and moving averages, despite some bullish momentum in the weekly RSI and mixed monthly signals.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and Bollinger Bands indicating bearish conditions, while the daily moving averages also reflect a bearish outlook. The weekly RSI shows bullish momentum, but the overall monthly indicators remain mixed, with the KST showing bullish on a monthly basis. Dow Theory suggests a mildly bullish stance on the weekly timeframe, but with no clear trend on the monthly. The stock's recent performance against the Sensex has been negative across multiple time frames, further supporting the bearish sentiment.

View full answer

How has been the historical performance of Rainbow Child.?

15-Nov-2025

Rainbow Child has shown consistent growth over the past six years, with net sales increasing from 650.05 Cr in Mar'21 to 1,515.87 Cr in Mar'25, and profit after tax rising from 39.57 Cr to 244.23 Cr. The company has eliminated long-term debt and improved cash flow, indicating strong financial health.

Answer:<BR>The historical performance of Rainbow Child shows a consistent growth trend across various financial metrics over the past six years.<BR><BR>Breakdown:<BR>Rainbow Child's net sales have increased significantly from 650.05 Cr in Mar'21 to 1,515.87 Cr in Mar'25, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 719.39 Cr in Mar'20 to 1,515.87 Cr in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 173.10 Cr in Mar'21 to 540.90 Cr in Mar'25, although the operating profit margin slightly decreased from 33.07% in Mar'24 to 32.32% in Mar'25. Profit before tax rose from 55.70 Cr in Mar'21 to 330.00 Cr in Mar'25, while profit after tax increased from 39.57 Cr in Mar'21 to 244.23 Cr in Mar'25, showcasing improved profitability. The total assets of the company grew from 1,018.89 Cr in Mar'20 to 2,347.40 Cr in Mar'25, indicating a solid expansion in the asset base. Furthermore, the company has eliminated long-term borrowings, achieving a total debt of 0.00 Cr in Mar'25, which reflects a strong financial position. Cash flow from operating activities has also improved, rising from 142.00 Cr in Mar'21 to 395.00 Cr in Mar'25, contributing to a net cash inflow of 10.00 Cr in Mar'25. Overall, Rainbow Child has demonstrated robust growth and financial health over the years.

View full answer

Who are the top shareholders of the Rainbow Child.?

17-Jul-2025

The top shareholders of Rainbow Child include Ramesh Kancharla with 31.04%, 23 mutual funds holding 11.47%, and 188 foreign institutional investors with 23.69%. The highest public shareholder is the DSP Aggressive Hybrid Fund at 4.27%, while individual investors own 10.34% of the shares.

The top shareholders of Rainbow Child include the promoters, with Ramesh Kancharla holding the highest individual stake at 31.04%. Additionally, the company has significant institutional investment, with 23 mutual funds collectively holding 11.47% and 188 foreign institutional investors (FIIs) holding 23.69%. The highest public shareholder is the DSP Aggressive Hybrid Fund, which holds 4.27%. Individual investors also have a notable presence, owning 10.34% of the shares.

View full answer

Is Rainbow Child. overvalued or undervalued?

09-Jun-2025

As of June 12, 2023, Rainbow Child is considered very expensive and overvalued with a PE ratio of 58.94, a Price to Book Value of 9.77, and an EV to EBITDA ratio of 29.64, despite a strong three-year stock performance of 199.47%.

As of 12 June 2023, the valuation grade for Rainbow Child. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 58.94, a Price to Book Value of 9.77, and an EV to EBITDA ratio of 29.64. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Rainbow Child. has a higher PE ratio than Max Healthcare Institute Ltd. at 100.29 and Apollo Hospitals Enterprise Ltd. at 69.03, both of which are also categorized as very expensive. The PEG ratio of 4.86 further underscores the overvaluation, especially when compared to peers like Narayana Hrudayalaya Ltd. with a PEG of 37.59. Despite a strong stock performance over the past three years, with a return of 199.47%, the current valuation metrics indicate that Rainbow Child. is not justified at its current price of 1408.40.

View full answer

Has Rainbow Child. declared dividend?

06-Jun-2025

Rainbow Childrens Medicare Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of June 27, 2025. The dividend yield is 0.21%, and total returns have varied across periods, showing significant growth over the long term despite short-term declines.

Rainbow Childrens Medicare Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.08%, the dividend return was 0.18%, resulting in a total return of -13.9%.<BR><BR>Over the past year, the price return was 8.36%, the dividend return was 0.46%, leading to a total return of 8.82%.<BR><BR>In the 2-year period, the price return was 52.26%, the dividend return was 0.94%, culminating in a total return of 53.2%.<BR><BR>For the 3-year period, the price return was 196.48%, the dividend return was 2.53%, resulting in a total return of 199.01%.<BR><BR>In the 4-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Similarly, in the 5-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Overall, Rainbow Childrens Medicare Ltd has declared a dividend and has shown varying total returns across different periods, with significant growth in the longer terms despite some negative performance in the short term. The dividend yield indicates a modest return relative to the share price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROCE of 19.70%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.64 times

 
3

Poor long term growth as Operating profit has grown by an annual rate 15.44% of over the last 5 years

 
4

Positive results in Mar 26

5

With ROCE of 18.7, it has a Very Expensive valuation with a 7.1 Enterprise value to Capital Employed

6

High Institutional Holdings at 38.37%

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 14,376 Cr (Small Cap)

stock-summary
P/E

51.00

stock-summary
Industry P/E

60

stock-summary
Dividend Yield

0.21%

stock-summary
Debt Equity

0.27

stock-summary
Return on Equity

16.97%

stock-summary
Price to Book

8.74

Revenue and Profits:
Net Sales:
460 Cr
(Quarterly Results - Mar 2026)
Net Profit:
77 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.21%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.31%
0.31%
27.62%
6 Months
5.84%
0.26%
6.1%
1 Year
-1.99%
0.44%
-1.55%
2 Years
7.98%
0.74%
8.72%
3 Years
49.83%
0.99%
50.82%
4 Years
226.91%
3.08%
229.99%
5 Years
0%
0%
0.0%

Latest dividend: 3 per share ex-dividend date: Jun-27-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Rainbow Childrens Medicare Ltd Falls 3.00%: Mixed Technicals and Valuation Shift Shape Week

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

01-Jun-2026 | Source : BSE

Earnings call transcript for the financial results Q4 FY26

March 31 2026

27-May-2026 | Source : BSE

Financial Results approved in the Board Meeting held on May 23 2026.

March 31 2026

27-May-2026 | Source : BSE

Financial Results approved in the Board Meeting dated March 23 2026.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Rainbow Childrens Medicare Ltd has declared 35% dividend, ex-date: 21 Jul 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
15.00%
EBIT Growth (5y)
15.44%
EBIT to Interest (avg)
5.00
Debt to EBITDA (avg)
1.65
Net Debt to Equity (avg)
0.27
Sales to Capital Employed (avg)
0.70
Tax Ratio
21.41%
Dividend Payout Ratio
14.03%
Pledged Shares
0
Institutional Holding
38.37%
ROCE (avg)
20.01%
ROE (avg)
17.67%

Valuation key factors

Factor
Value
P/E Ratio
51
Industry P/E
60
Price to Book Value
8.74
EV to EBIT
37.74
EV to EBITDA
27.29
EV to Capital Employed
7.07
EV to Sales
8.72
PEG Ratio
3.46
Dividend Yield
0.21%
ROCE (Latest)
18.74%
ROE (Latest)
16.97%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 24 Schemes (17.46%)

FIIs

Held by 126 FIIs (17.24%)

Promoter with highest holding

Ramesh Kancharla (31.03%)

Highest Public shareholder

Icici Prudential Smallcap Index Fund (5.19%)

Individual Investors Holdings

10.7%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 3.24% vs 0.15% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6.22% vs -3.61% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "459.90",
          "val2": "445.45",
          "chgp": "3.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "144.70",
          "val2": "146.98",
          "chgp": "-1.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "20.50",
          "val2": "20.20",
          "chgp": "1.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.54",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "77.04",
          "val2": "72.53",
          "chgp": "6.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "31.46%",
          "val2": "33.00%",
          "chgp": "-1.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 6.69% vs 20.62% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 8.74% vs 13.96% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "797.73",
          "val2": "747.68",
          "chgp": "6.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "252.49",
          "val2": "240.80",
          "chgp": "4.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "36.93",
          "val2": "36.26",
          "chgp": "1.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "128.75",
          "val2": "118.40",
          "chgp": "8.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "31.65%",
          "val2": "32.21%",
          "chgp": "-0.56%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 8.50% vs 19.87% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 7.58% vs 12.68% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,243.18",
          "val2": "1,145.76",
          "chgp": "8.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "399.47",
          "val2": "375.15",
          "chgp": "6.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "57.13",
          "val2": "54.33",
          "chgp": "5.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "201.28",
          "val2": "187.09",
          "chgp": "7.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "32.13%",
          "val2": "32.74%",
          "chgp": "-0.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 12.35% vs 16.88% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 14.34% vs 12.18% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,703.08",
          "val2": "1,515.87",
          "chgp": "12.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "544.17",
          "val2": "489.89",
          "chgp": "11.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "77.62",
          "val2": "72.46",
          "chgp": "7.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.54",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "278.32",
          "val2": "243.42",
          "chgp": "14.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "31.95%",
          "val2": "32.32%",
          "chgp": "-0.37%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
459.90
445.45
3.24%
Operating Profit (PBDIT) excl Other Income
144.70
146.98
-1.55%
Interest
20.50
20.20
1.49%
Exceptional Items
-1.54
0.00
Consolidate Net Profit
77.04
72.53
6.22%
Operating Profit Margin (Excl OI)
31.46%
33.00%
-1.54%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 3.24% vs 0.15% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 6.22% vs -3.61% in Dec 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
797.73
747.68
6.69%
Operating Profit (PBDIT) excl Other Income
252.49
240.80
4.85%
Interest
36.93
36.26
1.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
128.75
118.40
8.74%
Operating Profit Margin (Excl OI)
31.65%
32.21%
-0.56%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 6.69% vs 20.62% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 8.74% vs 13.96% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,243.18
1,145.76
8.50%
Operating Profit (PBDIT) excl Other Income
399.47
375.15
6.48%
Interest
57.13
54.33
5.15%
Exceptional Items
0.00
0.00
Consolidate Net Profit
201.28
187.09
7.58%
Operating Profit Margin (Excl OI)
32.13%
32.74%
-0.61%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 8.50% vs 19.87% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 7.58% vs 12.68% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,703.08
1,515.87
12.35%
Operating Profit (PBDIT) excl Other Income
544.17
489.89
11.08%
Interest
77.62
72.46
7.12%
Exceptional Items
-1.54
0.00
Consolidate Net Profit
278.32
243.42
14.34%
Operating Profit Margin (Excl OI)
31.95%
32.32%
-0.37%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 12.35% vs 16.88% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 14.34% vs 12.18% in Mar 2025

stock-summaryCompany CV
About Rainbow Childrens Medicare Ltd stock-summary
stock-summary
Rainbow Childrens Medicare Ltd
Small Cap
Hospital
Rainbow Childrens Medicare Limited was originally incorporated as `Rainbow Children's Medicare Private Limited' as Private Company dated August 7, 1998, issued by the Registrar of Companies, Hyderabad at Telangana. Subsequently, the Company converted into a Public Limited, and name of the Company was changed to `Rainbow Children's Medicare Limited' via fresh Certificate Incorporated issued by the RoC on November 20, 2021.
Company Coordinates stock-summary
Icon
No Company Details Available